3 March 2022 - Nymox Pharmaceutical Corporation is pleased to announce today that it has submitted the Company’s new drug application to the FDA for fexapotide triflutate to seek marketing approval in the U.S. for fexapotide triflutate for the treatment of men with benign prostatic hyperplasia.

Nymox intends to submit applications in other major markets in the near term and will provide updates at the appropriate times in due course.

Read Nymox press release